Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery

Pereda, Ricardo; González, Daniel; Rivero, Hubert Blas; Rivero, Juan; Pérez, Albadio; Lopez, Lissette del Rosario; Mezquia, Natacha; Venegas, Rafael; Betancourt, Julio Raul; Domínguez, Rodolfo Emilio

doi:10.1101/2020.07.28.20157974

Cited by 5 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it has been reported that inborn errors of type I IFN immunity are associated with severe COVID-19 [ 96 ] since the low type I IFN activity triggers IL6 and NF-α mediated pro-inflammatory responses and cytokine storm [ 97 ]. Recent reports suggest that IFN-α therapy could be a potential management strategy for COVID-19 [ 98 , 99 ]. Therefore, IFN-α treatment for COVID-19 patients with CKDs needs further evaluation.…”

Section: Discussionmentioning

confidence: 99%

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

et al. 2021

View full text Add to dashboard Cite

It is well established that pre-existing comorbid conditions such as hypertension, diabetes, obesity, cardiovascular diseases (CVDs), chronic kidney diseases (CKDs), cancers, and chronic obstructive pulmonary disease (COPD) are associated with increased severity and fatality of COVID-19. The increased death from COVID-19 is due to the unavailability of a gold standard therapeutic and, more importantly, the lack of understanding of how the comorbid conditions and COVID-19 interact at the molecular level, so that personalized management strategies can be adopted. Here, using multi-omics data sets and bioinformatics strategy, we identified the pathway crosstalk between COVID-19 and diabetes, hypertension, CVDs, CKDs, and cancers. Further, shared pathways and hub gene-based targets for COVID-19 and its associated specific and combination of comorbid conditions are also predicted towards developing personalized management strategies. The approved drugs for most of these identified targets are also provided towards drug repurposing. Literature supports the involvement of our identified shared pathways in pathogenesis of COVID-19 and development of the specific comorbid condition of interest. Similarly, shared pathways- and hub gene-based targets are also found to have potential implementations in managing COVID-19 patients. However, the identified targets and drugs need further careful evaluation for their repurposing towards personalized treatment of COVID-19 cases having pre-existing specific comorbid conditions we have considered in this analysis. The method applied here may also be helpful in identifying common pathway components and targets in other disease-disease interactions too.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Such an effect rather might be by the previously reported anti-SARS-CoV-2 activity of type I IFNs when administered either by the parenteral route or inhaled. 26 …”

Section: Resultsmentioning

confidence: 99%

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Cruz

Baladrón

Rittoles

et al. 2020

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors in vitro ; however, no anti-CK2 clinical approach has been investigated in COVID-19. This trial aimed to explore the safety and putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer patients. A monocentric, controlled, and therapeutic exploratory trial of intravenous CIGB-325 in adults hospitalized with COVID-19 was performed. Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care alone (10 patients). Adverse events were classified by the WHO Adverse Reaction Terminology. Parametric and nonparametric statistical analyses were performed according to the type of variable. Considering the small sample size, differences between groups were estimated by Bayesian analysis. CIGB-325 induced transient mild and/or moderate adverse events such as pruritus, flushing, and rash in some patients. Both therapeutic regimens were similar with respect to SARS-CoV-2 clearance in nasopharynx swabs over time. However, CIGB-325 significantly reduced the median number of pulmonary lesions (9.5 to 5.5, p = 0.042) at day 7 and the proportion of patients with such an effect was also higher according to Bayesian analysis (pDif > 0; 0.951). Also, CIGB-325 significantly reduced the CPK ( p = 0.007) and LDH ( p = 0.028) plasma levels at day 7. Our preliminary findings suggest that this anti-CK2 clinical approach could be combined with standard-of-care in COVID-19 in larger studies.

show abstract

“…Apesar da pouca existência de dados comprobatórios, sua influência positiva foi evidenciada, os estudos existentes mostraram que o uso dos interferons tem intervenção positiva na qualidade do tratamento dos pacientes diminuindo o tempo de permanência nos hospitais, o tempo de internações em UTI's e também a necessidade de utilizar aparelhos respiratórios. É importante ressaltar que os IFN diminuíram significativamente o número de óbitos relacionados à COVID-19 44 .…”

Section: Discussionunclassified

“…A droga apresentou uma redução significativa na mortalidade 43 . Pareda et al 44 avaliaram a influência dos IFN no tempo de permanência no hospital nos pacientes infectados com COVID-19. Os dados das análises feitas, evidenciaram que houve melhora no tratamento dos pacientes e diminuição do tempo de permanência nos leitos hospitalares, aumentando a probabilidade de sobrevivência dos pacientes quando comparado a outros medicamentos.…”

Section: Dexametasonaunclassified

Tratamento Da Covid-19 -Protocolos Atuais E Perspectivas Futuras

Ferreira¹,

Lopes²,

Morais³

et al. 2021

RECIMA21

View full text Add to dashboard Cite

Considerando a relevância da covid-19 na atualidade, este trabalho teve como objetivo apontar as principais drogas que se tornaram alvo de estudo e uso clínico no tratamento da doença. Foi utilizada a metodologia de revisão narrativa da literatura sobre os tratamentos até então testados para a covid-19, onde se reuniu os estudos de maior relevância e robustez sobre cada medicamento. Das drogas avaliadas, algumas apresentaram influência positiva no tempo de cura e diminuição dos sintomas causados pela doença. Dentre os medicamentos estudados, o remdesivir foi o de maior destaque, reduzindo o tempo de permanecia na UTI e também a taxa de mortalidade. A heparina, apresentou grande influência positiva ligada aos casos com tendência ao desenvolvimento de trombose. A dexametasona demonstrou poder de redução da chance de mortalidade e a ivermectina atuou na redução do tempo de duração da doença. Outras drogas como Azitromicina e Hidroxicloroquina não se mostraram eficazes nos estudos de maior relevância e não foram encontrados dados que justificassem seu uso para o tratamento da Covid-19. Apesar da pouca quantidade de dados que comprovem seu efeito contra a Covid-19, os interferons apresentaram potencial positivo e reduziram o tempo de permanência dos pacientes no hospital. Até o momento, nenhum medicamento específico foi aprovado para tratar a covid-19. O tratamento da doença se concentra principalmente nos cuidados de suporte. Contudo, nossa pesquisa bibliográfica evidenciou que alguns protocolos medicamentosos apresentaram um desfecho positivo quando comparado ao tratamento sem a utilização de nenhum fármaco.

show abstract

Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery

Cited by 5 publications

References 18 publications

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Tratamento Da Covid-19 -Protocolos Atuais E Perspectivas Futuras

Contact Info

Product

Resources

About